Ramucirumab
Cytostatic · Monoclonal antibody
Indications
In combination with docetaxel for metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy. In combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first-line bevacizumab, oxaliplatin and fluoropyrimidine containing regimen.
Dosage
Adults: Non-small cell lung cancer: 10 mg/kg IV infused over 1 hr prior to docetaxel (75 mg/m²) IV infusion on day 1 of a 21-day cycle. Gastric cancer: Single agent or in combination with paclitaxel: 8 mg/kg IV q2wk; infuse over 1 hr. Paclitaxel dose (if given in combination): 80 mg/m² once weekly for 3 weeks of every 28-day cycle. When given in combination, administer ramucirumab prior to administration of paclitaxel. Colorectal cancer: 8 mg/kg IV q2wk; administer by IV infusion over 60 minutes prior to FOLFIRI administration.
Administration
Administer diluted Ramucirumab infusion via infusion pump over 1 hr through a separate infusion line. Use of a protein sparing 0.22 micron filter is recommended. Flush the line with sterile NaCl (0.9%) solution for injection at the end of the infusion. Reconstitution: Calculate the dose and the required volume of Ramucirumab needed to prepare the infusion solution. Withdraw the required volume of Ramucirumab and further dilute with only 0.9% NaCl injection in an IV infusion container to a final volume of 250 mL. Gently invert the container to ensure adequate mixing. Do not freeze or shake the infusion solution. Compatibility: Do not use dextrose containing solutions. Stability: Store vials in a refrigerator at 2°C-8°C (36°F-46°F) until time of use. Keep the vial in the outer carton in order to protect from light. Store diluted infusion for no more than 24 hours at 2°C-8°C (36°F- 46°F)…
Adverse Effects
Fatigue, asthaenia, neutropenia, diarrhoea, epistaxis, peripheral edema, stomatitis, proteinuria, hypertension, Infusion-related reactions, hypertension grade 3-4, thrombocytopenia, hypoalbuminaemia.
Risk Factor (Pregnancy/Lactation)
Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Hemorrhage, gastrointestinal perforation, impaired wound healing.
Pharmacokinetics
Half-life elimination: 14 days.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.